SELLAS Life Sciences (SLS) Gross Profit (2012 - 2022)

SELLAS Life Sciences (SLS) has 7 years of Gross Profit data on file, last reported at $900000.0 in Q1 2022.

• On a quarterly basis, Gross Profit fell 83.93% year-over-year to $900000.0 in Q1 2022; TTM through Dec 2022 was $900000.0, a 87.84% decrease from a year earlier, with the FY2022 full-year figure at $900000.0, down 87.84% from the prior year.
• Gross Profit for Q1 2022 stood at $900000.0, down from $1.8 million in the prior quarter.
• Over the last five years, Gross Profit for SLS reached as high as $5.6 million in Q1 2021 and fell as low as $900000.0 in Q1 2022.
• Historically, Gross Profit has averaged $2.6 million across 3 years, with a median of $1.8 million in 2020.
• On a YoY basis, Gross Profit climbed as much as 83.93% in 2022 and fell as far as 83.93% in 2022.
• Year by year, Gross Profit stood at $1.9 million in 2020, then dropped by 5.26% to $1.8 million in 2021, then slumped by 50.0% to $900000.0 in 2022.
• Per Business Quant data, the three most recent Gross Profit figures were $900000.0 in Q1 2022, $1.8 million in Q2 2021, and $5.6 million in Q1 2021.